FDA and state rules, for what you actually buy.

Must a pharmacy located in another state hold a license/registration from this state to ship prescriptions (including patient-specific 503A compounded preparations) to patients or practitioners here?

26 V.S.A. §§2061 and 2064 bar any drug outlet from operating until it is licensed, and the Board of Pharmacy rules (effective Feb. 1, 2026) state that no drug outlet may operate in Vermont, including as a nonresident drug outlet, unless licensed (Rules 7-3, 10-9). A nonresident drug outlet is defined as one outside Vermont that dispenses prescription drugs or devices to a person in Vermont by mail, shipping or delivery (Rule 1-25). Applicants must show licensure in good standing in their home state, register their business name with the Vermont Secretary of State, disclose ownership, and submit an inspection report. The inspection must assess compliance with law and USP, come from the home-state board, NABP, FDA or another recognized third party, and be no older than 2 years for compounding, home-infusion and nuclear pharmacies or 3 years for others (Rule 7-4(b)). A pharmacy that compounds must also register with the compounding specialty 'regardless of products shipped to Vermont' (Rule 10-4(a); OPR instructions), and a new inspection report is required at each renewal (Rule 6-2). Licensing is administered by the Office of Professional Regulation (OPR).

The Board rules were rewritten effective Feb. 1, 2026. On the nonresident PIC form (April 2026), the PIC certifies that the pharmacy can produce records within 72 hours and offers a toll-free line (at least 6 days and 40 hours a week) printed on each label. The rules reviewed do not expressly require the nonresident PIC to hold a Vermont license, since Rule 8-7 (pharmacy manager) applies only to in-state pharmacies. Pharmacies shipping controlled substances must provide DEA information and register with the Vermont Prescription Monitoring System. Licenses renew biennially (26 V.S.A. §2061(a)); fees are listed in 26 V.S.A. §2046.

May a 503A (traditional) pharmacy dispense or distribute compounded preparations to a practitioner for office use (administration in the office, not patient-specific)? The federal position is that 503A requires patient-specific prescriptions; this is what the state pharmacy act and board rules allow.

Board Rule 10-4(c) (effective Feb. 1, 2026) permits compounding only (1) pursuant to a practitioner's patient-specific order based on the practitioner-patient-pharmacist-compounder relationship; (2) in limited quantities and for a specific patient, based on a history of routine, regularly observed prescribing patterns; or (3) for veterinary use, including resale by veterinary clinics. The rule also requires compliance with 21 U.S.C. §353a (section 503A) and USP <795>, <797> and <800>. There is no allowance for non-patient-specific office-use compounding for human patients, which matches FDA's position under 503A. The rule covers any pharmacy, in state or out of state, that dispenses to people in Vermont. Office stock can come from 503B outsourcers, which must hold their own Vermont registration (Rule 10-5).

This reflects the rules as rewritten effective Feb. 1, 2026. The only express non-patient-specific allowance is veterinary. Waivers are possible only in extraordinary circumstances (Rule 12-1). The 26 V.S.A. ch. 36 statute itself is silent on office use.

Does the state require an FDA-registered 503B outsourcing facility located outside the state to hold a state license/registration (as an outsourcing facility, nonresident manufacturer, wholesaler or pharmacy) before shipping into the state?

26 V.S.A. §2061(b)(7) lists 'Outsourcing' as a drug outlet license class, and §2064 bars operating a drug outlet without a license. Board Rule 10-5 (eff. Feb. 1, 2026) states that a 503B outsourcer doing business in Vermont must register as a 503B outsourcer whether or not it is physically located in Vermont. It must name the licensed pharmacist directly supervising compounding and adhere to FD&C Act §503B, cGMP and FDA guidance. Nonresident applicants must submit an inspection report and licensure verification. An outsourcer that has not yet had its initial FDA inspection may submit a statement to that effect on letterhead (Rule 7-4(b); OPR instructions). Outsourcers also report FDA inspections and actions and any recalls from the past 5 years. 503B outsourcers are excluded from the definition of 'pharmacy' and do not need a compounding pharmacy registration (Rules 1-30, 10-4(a)).

Statutory fees are $800 initial and $570 biennial renewal for an 'Outsourcing drug outlet' (26 V.S.A. §2046). The OPR instructions ask for an inspection no older than 3 years. The rules do not expressly require the supervising pharmacist to hold a Vermont license. An outsourcer that also dispenses patient-specific prescriptions to Vermont residents may need a pharmacy license too; confirm with OPR (SOS.OPRLicensing2@vermont.gov, 802-828-1505).

Has the state signed FDA's standard Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products (October 2020)? If not, FD&C Act §503A limits its 503A pharmacies' out-of-state distribution to 5% of total prescription orders (currently not enforced by FDA pending rulemaking).

Signing the standard MOU means the state board agrees to investigate complaints about compounded drugs its 503A pharmacies ship out of state and to identify and report to FDA pharmacies that distribute "inordinate amounts" interstate (more than 50% of their compounded prescriptions); in exchange, the statutory 5% out-of-state cap in FD&C Act §503A(b)(3)(B) does not apply to that state's pharmacies. FDA lists only Colorado, Kentucky and New Hampshire as signatories; Vermont is not among them. For a non-signing state, FD&C Act §503A(b)(3)(B)(ii) caps a 503A pharmacy's out-of-state distribution of compounded drugs at 5% of its total prescription orders. FDA now considers the October 2020 standard MOU suspended (it does not expect signatory states to carry out MOU activities and will not sign new ones) and is not enforcing the 5% limit until a final rule and an updated MOU are published; FDA's rulemaking (RIN 0910-AI71) listed a proposed rule for 11/2026 in the Fall 2025 Unified Agenda.

The FDA list of signed MOUs (current as of 2023-01-23) is older than 2 years, but FDA stopped entering new agreements under the 2020 MOU in October 2022, so no state can have signed since. The FDA "Compounding Information for States" page (current as of 2026-08-28) still describes the MOU as awaiting rulemaking. Pending: FDA proposed rule on 503A distribution (RIN 0910-AI71, NPRM projected 11/2026); H.R. 5316 (introduced 2025-09-11, referred to House Energy & Commerce) would remove the MOU provision from §503A.

Besides DEA registration, does the state require practitioners to hold a separate state controlled substance registration, license or permit to prescribe, administer or dispense controlled substances (e.g. testosterone, Schedule III)? "Conditional" means a state registration is needed only in some settings, such as keeping controlled-substance stock in the office.

18 V.S.A. 4206 requires anyone who prescribes or dispenses a regulated drug to hold a license from their respective professional board (or, if no board has jurisdiction, from the Department of Health), and 18 V.S.A. 4201 defines 'license' as the professional license issued by that board. 18 V.S.A. 4214 authorizes a licensed physician to prescribe, administer and dispense regulated drugs and to have them administered by nurses and assistants. Separately, 18 V.S.A. 4207 requires a Department of Health certificate of approval ($1, renewed each July 1) for hospitals, laboratories, nursing homes and any other person not covered by 4206 that possesses or administers regulated drugs.

Statute amended 2023 (Act 53). Whether a non-practitioner business entity (e.g. a clinic not owned by licensees) that stocks regulated drugs needs a 4207 certificate of approval was not confirmed. NP/PA prescriptive authority comes from their own boards.

Must a prescriber query the state Prescription Drug Monitoring Program before prescribing, and does the mandate cover Schedule III drugs such as testosterone? "Yes" means a mandate that reaches Schedule III; "conditional" means a mandate limited to certain drugs (e.g. opioids or benzodiazepines) or situations; "no" means no prescriber query mandate.

18 V.S.A. Sec. 4289(c) requires providers to query VPMS at least annually for patients on ongoing Schedule II-IV opioid treatment, when starting a Schedule II-IV controlled substance for nonpalliative long-term pain therapy of 90 days or more, the first time they prescribe a Schedule II-IV opioid for chronic pain, and before writing a replacement (lost or stolen) prescription for any Schedule II-IV controlled substance. The Department of Health VPMS rule (section 6.2) adds the first opioid prescription for pain over 10 pills, the first time a provider prescribes a benzodiazepine, emergency or urgent care opioid requests, and buprenorphine prescribing (first time and at least twice a year). Testosterone would trigger a query only for a replacement prescription. Licensing boards consider these requirements in disciplinary proceedings.

Statute last amended 2019, No. 82. The VPMS rule PDF posted by the Health Department shows 'Effective Date 7.1.2017' (source older than 2 years - possibly stale); PDMP TTAC cites 'CVR 12-5-102:4.0 (2024)', suggesting a later version may exist that was not opened. The Department also has a separate Rule Governing the Prescribing of Opioids for Pain.

May physicians dispense prescription drugs (not just administer them) directly to patients from their practice? "Yes" means allowed under standard rules (labeling, records, and at most a simple notice to the board); "conditional" means a separate dispensing registration, permit or license, or quantity, day-supply or drug-category limits; "no" means prohibited except narrow exceptions.

A vendor summary reports that Vermont physicians may dispense to patients under their care with no separate dispensing license, following state and federal storage and labeling rules, and that dispensed controlled substances are reported to the Vermont Prescription Monitoring System. The statute and rule text were not reviewed.

Confirm with the Vermont Board of Medical Practice or Office of Professional Regulation (Board of Pharmacy).

For a patient located in the state: must the prescriber hold this state's license (or a telehealth registration or special license), is an in-person exam required before prescribing (generally or for controlled substances), are there state limits on prescribing Schedule III drugs such as testosterone by telehealth, and is the state an Interstate Medical Licensure Compact member? "Yes" means a state license and the in-person standard of care apply (opioid-only or Schedule II-only limits are described but do not change the answer); "conditional" means extra state conditions such as a telehealth registration route, an in-person exam requirement, controlled-substance limits reaching Schedule III, or registration of telehealth businesses. Federal DEA rules apply on top.

(1) A clinician not licensed in Vermont must obtain a telehealth license or telehealth registration to treat Vermont patients by telehealth (26 V.S.A. 3053); for MDs, PAs and podiatrists the Board of Medical Practice has offered these since Aug. 1, 2024 - a non-renewable registration valid 120 days for up to 10 unique patients, or a renewable telehealth license for up to 20 unique patients per two-year term, with no in-person care in Vermont - while osteopathic physicians go through the Office of Professional Regulation, which still uses an Interim Telehealth Registration pending final rules. (2) Vermont providers may prescribe after an appropriate exam in person, through telemedicine or by electronic instrumentation, held to the same standards as in-person care (18 V.S.A. 9361(b), per CCHP), so no in-person exam is required. (3) No Vermont-specific telehealth limit on controlled substances such as testosterone was found; OUD medications may be prescribed via telehealth under federal requirements (18 V.S.A. 4752, per CCHP). (4) IMLC: member (issues IMLC licenses as a non-principal-license state).

CCHP's Vermont page describes the telehealth registration/license as 'not in effect until rules are in place' - that is true only for OPR professions (including osteopathy); the Board of Medical Practice (MDs, PAs, podiatrists) has issued them since 2024-08-01. OPR's draft telehealth licensure rules had a public comment period closing 2026-08-04. 18 V.S.A. 9361 and 4752 were read via CCHP.

Who may administer botulinum toxin and dermal fillers (physicians, PAs, NPs, RNs, LPNs, estheticians, dentists), under what supervision (on-site vs available), and must a physician/NP/PA perform a prior good-faith exam?

The 2024 joint statement of the Office of Professional Regulation and the Boards of Medical Practice, Osteopathic Medicine, Nursing and Pharmacy on IV therapy clinics and medical spas states that it is illegal to administer any prescription drug without a valid prescription. A valid prescription requires a practitioner-patient relationship, an appropriate evaluation, a diagnosis, a treatment plan and documentation. MDs/DOs may delegate only to individuals whose licensed scope covers the task, and the task must remain under the physician's control; RNs may administer prescribed drugs. Vermont has no separate rule on who may inject botulinum toxin or fillers.

The joint statement is written mainly about IV products; applying its valid-prescription and anti-standing-order reasoning to neuromodulators and fillers is an inference, though the statement's title covers medical spas and its rule is stated for all prescription drugs.

What does the state require for elective IV hydration/vitamin (incl. NAD+) therapy: who may start IVs, is a patient-specific order or good-faith exam required before a patient's first IV, are standing orders allowed, and are there rules for mobile IV services?

Per the 2024 joint statement, only MDs, DOs, PAs, APRNs and naturopathic physicians with a prescribing endorsement may prescribe IV products, and patients may not self-select a "cocktail" from a menu. A valid prescription requires a practitioner-patient relationship, evaluation, diagnosis, treatment plan and documentation; standing orders from IV clinic medical directors are not valid prescriptions, and compounding can never occur under a standing order. Mixing additives into saline is compounding, which PAs, APRNs and RNs may not do in IV hydration clinics or med spas (LPNs, LNAs, cosmetologists and estheticians never). IVs may be administered by MDs, DOs, PAs, APRNs, prescribing NDs, RNs, and LPNs only with documented competency under direct supervision of a prescriber or RN.

Does the state enforce the corporate practice of medicine doctrine (non-physicians may not own medical practices or employ physicians), and how does that affect med spa ownership?

Permit Health's 2025 guide lists Vermont among non-CPOM states, citing only the professional corporation statute and certificate-of-need law (18 V.S.A. §§9431–9445). MedPath Compliance (reviewed 2026-06-20) also lists Vermont as 'No' and reports H.583 (2026) pending, which would establish a CPOM doctrine and ownership reporting.

Status of H.583 after June 2026 not confirmed.

Who may perform laser/IPL/RF aesthetic procedures (laser hair removal, resurfacing): physicians only, delegated to RNs/PAs, or licensed electrologists/estheticians/laser technicians with state certification?

The Vermont Board of Medical Practice's list of policies (checked 2026-09-23) has no policy on lasers, cosmetic procedures or delegation beyond the 2024 IV therapy/medical spa joint statement, which says MDs/DOs may delegate only tasks within the delegate's licensed scope and under the physician's control.

Does the state license clinical laboratories itself, beyond federal CLIA certification, including out-of-state labs that test specimens from the state?

Most states rely on federal CLIA certification alone. The states confirmed in this research as issuing their own lab licenses are California, New York, Pennsylvania, Maryland and Rhode Island (which also reach out-of-state labs testing specimens from their residents), plus Nevada, Washington, Massachusetts, New Jersey and New Hampshire (labs located in the state). Vermont was not among them, but this research did not confirm its statutes. Vermont's CLIA state agency is New Hampshire DHHS, Health Facilities Administration, which serves Vermont labs (CLIA@dhhs.nh.gov, 603-271-9048); it can confirm whether any state license or permit applies, including to out-of-state labs.

Absence of a state license was not verified against the state's statutes or rules.

May consumers order their own lab tests without a practitioner order (direct access testing)? A practitioner-ordered panel is always fine; this matters for take-home and consumer test kits.

ADLM (formerly AACC) reported in 2019 that 37 states and DC let consumers order some or all tests directly, but it did not publish the state list, and this research did not confirm Vermont's rule. Vermont's lab regulator (CLIA state agency) is New Hampshire DHHS, Health Facilities Administration, which serves Vermont labs (CLIA@dhhs.nh.gov, 603-271-9048). The question matters for take-home and consumer test kits, not for panels a clinician orders.

The ADLM figure dates from 2019 (older than 2 years).

Has the state enacted a law or rule specifically about stem cell, exosome or regenerative-medicine therapies (notice/disclosure duties, permission for certain non-FDA-approved uses, or Right to Try extensions covering them)?

Act 61 of 2021 (S.22), codified at 18 V.S.A. ch. 90, does not ban unapproved products. It requires a posted notice ('THIS NOTICE MUST BE PROVIDED TO YOU UNDER VERMONT LAW...') at the entrance and in patient areas, the notice in all advertising, and a patient-signed disclosure form before each administration, kept in the chart. 'Stem cell and stem cell-related products' (18 V.S.A. §4501) covers human cells from bone marrow, adipose, amniotic membrane, umbilical cord blood (when not autologous or from a first- or second-degree relative), placenta and other sources, plus 'intracellular or extracellular components or vesicles' and amniotic fluid. The law lists some exemptions. It is enforced by the Board of Medical Practice and the Office of Professional Regulation. Federal FDA rules still apply regardless of state law: stem cell, birth-tissue and exosome products are regulated by FDA, and a state law cannot make an unapproved biologic FDA-approved.

This is the only law found that expressly reaches exosome and vesicle products. The Board newsletter is from July 2022 (older than 2 years); check the current statute for exemptions.

Does the state have cosmetic or sunscreen requirements beyond federal MoCRA, such as ingredient bans (PFAS, formaldehyde, phthalates), ingredient reporting, sunscreen-ingredient bans, or bans on selling animal-tested cosmetics?

Act 131 of 2024 (S.25; 9 V.S.A. §§2494a-2494b) bars intentionally added ortho-phthalates, PFAS, formaldehyde, methylene glycol, mercury, 1,4-dioxane, isopropyl- and isobutylparaben, lead, asbestos, triclosan and m-phenylenediamine in cosmetic and menstrual products from Jan 1, 2026. From July 1, 2027, o-phenylenediamine, quaternium-15, styrene, octamethylcyclotetrasiloxane (D4) and toluene are added. 1,4-dioxane may not knowingly exceed 10 ppm. Technically unavoidable trace impurities are excepted.

Federal MoCRA and FDA cosmetic and OTC sunscreen rules apply in every state.